Holman 2017 — EXSCEL Exenatide Cardiovascular Outcomes

New England Journal of Medicine·September 28, 2017

Rury R. Holman, Maria A. Bethel, Robert J. Mentz, David R. Thompson, Francesca B. Lokhnygina, EXSCEL Study Group

Summary

EXSCEL showed once-weekly exenatide was noninferior to placebo for cardiovascular safety, but did not significantly reduce major adverse cardiovascular events.

Study Details

Study Design

Randomized placebo-controlled cardiovascular outcomes trial

Indication

Type 2 diabetes

Intervention

Once-weekly exenatide vs placebo

Species

Human

Sample Size

14,752 subjects

Risk of Bias Assessment

Sponsor-funded; pragmatic CVOT